Der wissenschaftliche Schwerpunkt des Institutes liegt in der Erforschung funktioneller molekularbiologischer Veränderungen von intrakraniellen Tumoren, welche sowohl mit der malignen Progression als auch der Infiltrationsneigung dieser Tumoren verbunden sind. Hierbei spielt auch die Identifikation prognose- und therapierelevanter Marker eine wichtige Rolle. Insbesondere Veränderungen des Tumorstoffwechsels sowie der Einfluss des Tumor-Mikromilieus werden mit mikromorphologischen, immunhistochemischen und modernen molekularbiologischen Techniken einschließlich tierexperimenteller Ansätze analysiert. Einen großen Stellenwert nimmt hierbei die Weiterentwicklung realitätsnaher Mausmodelle zur Erforschung von  Genese und gezielter, molekularer Therapie des Meningeoms ein.

Unsere Arbeiten werden durch verschiedene Drittmittelgeber gefördert, welche bei den einzelnen Projekten genannt werden.

Die Links zu den einzelnen Projekten finden Sie Untermenü.

Hier finden Sie unsere wichtigsten Publikationen zum Forschungsschwerpunkt  Meningeome. Mit diesen Tumoren befassen sich auch die zentralen Drittmittel-geförderten Projekte des Instituts.

Publikationen zu Meningeomen

• Molecular neuropathology of brain-invasive meningiomas.
  von Spreckelsen N, Kesseler C, Brokinkel B, Goldbrunner R, Perry A, Mawrin C.
  Brain Pathol. 2022 Mar;32(2):e13048. doi: 10.1111/bpa.13048.
• A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
  Mawrin C, Koch R, Waldt N, Sandalcioglu IE, Braunsdorf WEK, Warnke JP, Goehre F, Meisel HJ, Ewald C, Neyazii S, Schüller U, Kirches E.
  Brain Pathol. 2022 Mar;32(2):e13046. doi: 10.1111/bpa.13046.
• Introduction to the mini-symposium "molecular neuropathology of meningioma".
  Sahm F, Mawrin C.
  Brain Pathol. 2022 Mar;32(2):e13055. doi: 10.1111/bpa.13055.
• AKT1^E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363.
  John P, Waldt N, Liebich J, Kesseler C, Schnabel S, Angenstein F, Sandalcioglu IE, Scherlach C, Sahm F, Kirches E, Mawrin C.
  Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12780. doi: 10.1111/nan.12780. Epub 2021 Dec 30.
• Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.
  Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt A, Suwala AK, Wefers AK, Baumgarten P, Ricklefs F, Rushing EJ, Bewerunge-Hudler M, Ketter R, Schittenhelm J, Jaunmuktane Z, Leu S, Greenway FEA, Bridges LR, Jones T, Grady C, Serrano J, Golfinos J, Sen C, Mawrin C, Jungk C, Hänggi D, Westphal M, Lamszus K, Etminan N, Jungwirth G, Herold-Mende C, Unterberg A, Harter PN, Wirsching HG, Neidert MC, Ratliff M, Platten M, Snuderl M, Aldape KD, Brandner S, Hench J, Frank S, Pfister SM, Jones DTW, Reifenberger G, Acker T, Wick W, Weller M, Preusser M, von Deimling A, Sahm F; German Consortium on Aggressive Meningiomas (KAM).
  J Clin Oncol. 2021 Dec 1;39(34):3839-3852. doi: 10.1200/JCO.21.00784. Epub 2021 Oct 7.
• Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas.
  Kirches E, Sahm F, Korshunov A, Bluecher C, Waldt N, Kropf S, Schrimpf D, Sievers P, Stichel D, Schüller U, Schittenhelm J, Riemenschneider MJ, Karajannis MA, Perry A, Pietsch T, Boekhoff S, Capper D, Beck K, Paramasivam N, Schlesner M, Brastianos PK, Müller HL, Pfister SM, Mawrin C.
  Acta Neuropathol. 2021 Nov;142(5):873-886. doi: 10.1007/s00401-021-02351-x. Epub 2021 Sep 8.
• Clinical Characteristics and Magnetic Resonance Imaging-Based Prediction of the KLF4^K409Q Mutation in Meningioma.
  von Spreckelsen N, Waldt N, Timmer M, Goertz L, Reinecke D, Laukamp K, Pennig L, Grau S, Deckert M, Kirches E, Stavrinou P, Mawrin C, Goldbrunner R.
  World Neurosurg. 2021 Oct;154:e665-e670. doi: 10.1016/j.wneu.2021.07.119. Epub 2021 Jul 31.
• Crispr/Cas-based modeling of NF2 loss in meningioma cells.
  Waldt N, Kesseler C, Fala P, John P, Kirches E, Angenstein F, Mawrin C.
  J Neurosci Methods. 2021 May 15;356:109141. doi: 10.1016/j.jneumeth.2021.109141. Epub 2021 Mar 19.
• KLF4^K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment.
  von Spreckelsen N, Waldt N, Poetschke R, Kesseler C, Dohmen H, Jiao HK, Nemeth A, Schob S, Scherlach C, Sandalcioglu IE, Deckert M, Angenstein F, Krischek B, Stavrinou P, Timmer M, Remke M, Kirches E, Goldbrunner R, Chiocca EA, Huettelmaier S, Acker T, Mawrin C.
  Acta Neuropathol Commun. 2020 Apr 3;8(1):41. doi: 10.1186/s40478-020-00912-x.
• Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
  Waldt N, Scharnetzki D, Kesseler C, Kirches E, Stroscher N, Böhmer FD, Mawrin C.
  J Neurol Sci. 2020 Jan 15;408:116553. doi: 10.1016/j.jns.2019.116553. Epub 2019 Nov 9.
• [Molecular biology, diagnosis, and therapy of meningiomas].
  Mawrin C.
  Pathologe. 2019 Sep;40(5):514-518. doi: 10.1007/s00292-019-00653-2.
• The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
  Kirches E, Steffen T, Waldt N, Hebert E, Pachow D, Wilisch-Neumann A, Keilhoff G, Schneider T, Braunsdorf WEK, Warnke JP, Mawrin C.
  J Neurooncol. 2018 Jun;138(2):251-259. doi: 10.1007/s11060-018-2807-7. Epub 2018 Feb 21.
• Advances in meningioma genetics: novel therapeutic opportunities.
  Preusser M, Brastianos PK, Mawrin C.
  Nat Rev Neurol. 2018 Feb;14(2):106-115. doi: 10.1038/nrneurol.2017.168. Epub 2018 Jan 5.
• ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.
  Bähr O, Gross S, Harter PN, Kirches E, Mawrin C, Steinbach JP, Mittelbronn M.
  Oncol Lett. 2017 Nov;14(5):5443-5451. doi: 10.3892/ol.2017.6832. Epub 2017 Aug 28.
• Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.
  Brokinkel B, Hess K, Mawrin C.
  Neuro Oncol. 2017 Oct 1;19(10):1298-1307. doi: 10.1093/neuonc/nox071.
• Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
  Wallesch M, Pachow D, Blücher C, Firsching R, Warnke JP, Braunsdorf WEK, Kirches E, Mawrin C.
  J Neurol Sci. 2017 Sep 15;380:112-121. doi: 10.1016/j.jns.2017.07.009. Epub 2017 Jul 8.
• Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
  Yesilöz Ü, Kirches E, Hartmann C, Scholz J, Kropf S, Sahm F, Nakamura M, Mawrin C.
  Neuro Oncol. 2017 Aug 1;19(8):1088-1096. doi: 10.1093/neuonc/nox018.
• Animal models of meningiomas.
  Mawrin C.
  Chin Clin Oncol. 2017 Jul;6(Suppl 1):S6. doi: 10.21037/cco.2017.05.03. Epub 2017 Jun 4.
• DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
  Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.
  Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.
• Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
  Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E, Mawrin C.
  Eur J Cancer. 2017 Mar;73:9-21. doi: 10.1016/j.ejca.2016.12.004. Epub 2017 Jan 9.
• Looking for the needle in the haystack: Proteome-based identification of treatment targets in NF2-related nervous system tumors.
  Mawrin C.
  EBioMedicine. 2017 Feb;16:6-7. doi: 10.1016/j.ebiom.2017.01.044. Epub 2017 Feb 1.
• The mTOR signaling pathway as a treatment target for intracranial neoplasms.
  Pachow D, Wick W, Gutmann DH, Mawrin C.
  Neuro Oncol. 2015 Feb;17(2):189-99. doi: 10.1093/neuonc/nou164. Epub 2014 Aug 27.
• Re-evaluation of cytostatic therapies for meningiomas in vitro.
  Wilisch-Neumann A, Pachow D, Wallesch M, Petermann A, Böhmer FD, Kirches E, Mawrin C.
  J Cancer Res Clin Oncol. 2014 Aug;140(8):1343-52. doi: 10.1007/s00432-014-1683-6. Epub 2014 May 11.
• The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
  Wilisch-Neumann A, Kliese N, Pachow D, Schneider T, Warnke JP, Braunsdorf WE, Böhmer FD, Hass P, Pasemann D, Helbing C, Kirches E, Mawrin C.
  Clin Cancer Res. 2013 Oct 1;19(19):5402-12. doi: 10.1158/1078-0432.CCR-12-0299. Epub 2013 Aug 15.
• miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
  Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider MJ, Meese E, Panayotova-Dimitrova D, Gutmann DH, Mawrin C.
  Oncogene. 2013 Sep 26;32(39):4712-20. doi: 10.1038/onc.2012.468. Epub 2012 Oct 29.
• Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
  Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C.
  Eur J Cancer. 2012 Aug;48(12):1831-41. doi: 10.1016/j.ejca.2012.01.032. Epub 2012 Mar 3.
• Cytotoxic effects of statins and thiazolidinediones on meningioma cells.
  Gehring S, Tapia-Pérez JH, Kirches E, Firsching R, Keilhoff G, Schneider T, Mawrin C.
  J Neurooncol. 2011 May;102(3):383-93. doi: 10.1007/s11060-010-0351-1. Epub 2010 Aug 30.
• Pathological classification and molecular genetics of meningiomas.
  Mawrin C, Perry A.
  J Neurooncol. 2010 Sep;99(3):379-91. doi: 10.1007/s11060-010-0342-2. Epub 2010 Sep 1.
• Fatty acid synthase as a novel target for meningioma therapy.
  Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C.
  Neuro Oncol. 2010 Aug;12(8):844-54. doi: 10.1093/neuonc/noq004. Epub 2010 Feb 5.
• Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC.
  Mawrin C, Wolke C, Haase D, Krüger S, Firsching R, Keilhoff G, Paulus W, Gutmann DH, Lal A, Lendeckel U.
  Brain Pathol. 2010 Jan;20(1):200-10. doi: 10.1111/j.1750-3639.2009.00267.x. Epub 2009 Feb 18.
• Novel chromosomal aberrations in a recurrent malignant meningioma.
  Pelz AF, Klawunde P, Skalej M, Wieacker P, Kirches E, Schneider T, Mawrin C.
  Cancer Genet Cytogenet. 2007 Apr 1;174(1):48-53. doi: 10.1016/j.cancergencyto.2006.10.008.
• Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
  Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K.
  Clin Cancer Res. 2005 Jun 1;11(11):4074-82. doi: 10.1158/1078-0432.CCR-04-2550.
• mTORC1 inhibitors suppress meningioma growth in mouse models.
  Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C.
  Clin Cancer Res. 2013 Mar 1;19(5):1180-9. doi: 10.1158/1078-0432.CCR-12-1904. Epub 2013 Feb 13.
• Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
  Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jäger N, Santarius T, Tarpey PS, Stephens PJ, Andrew Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins VP, König R, Wiestler OD, Pfister SM, von Deimling A.
  Acta Neuropathol. 2013 Mar;125(3):351-8. doi: 10.1007/s00401-013-1093-x. Epub 2013 Feb 12.
• Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.
  Baia GS, Caballero OL, Orr BA, Lal A, Ho JS, Cowdrey C, Tihan T, Mawrin C, Riggins GJ.
  Mol Cancer Res. 2012 Jul;10(7):904-13.
• Loss of the protein-tyrosine phosphatase DEP-1/PTPRJ drives meningioma cell motility.
  Petermann A, Haase D, Wetzel A, Balavenkatraman KK, Tenev T, Gührs KH, Friedrich S, Nakamura M, Mawrin C, Böhmer FD.
  Brain Pathol. 2011 Jul;21(4):405-18.
• Pathological classification and molecular genetics of meningiomas.
  Mawrin C. and Perry A.
  J Neuro-Oncology, 2010 Sep;99(3):379-91. doi: 10.1007/s11060-010-0342-2. Epub 2010 Sep 1. Review.
• The microglial/macrophagic response at the tumour-brain border of invasive meningiomas.
  Grund S, Schittenhelm J, Roser F, Tatagiba M, Mawrin C, Kim YJ, Bornemann A.
  Neuropathol Appl Neurobiol. 2009 Feb;35(1):82-8.
• Genome wide expression profiling identifies specific deregulated pathways in meningioma.
  Keller A, Ludwig N, Backes C, Romeike BF, Comtesse N, Henn W, Steudel WI, Mawrin C, Lenhof HP, Meese E.
  Int J Cancer. 2009 Jan 15;124(2):346-51.
• Meningiomas do not express CD117 (KIT).
  Mawrin C, Evert M.
  Histopathology. 2007 Sep;51(3):426-7. No abstract available.
• Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas.
  Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A.
  Neuropathol Appl Neurobiol. 2006 Oct;32(5):525-31.
• Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9.
  Okuducu AF, Zils U, Michaelis SA, Mawrin C, von Deimling A.
  Cancer. 2006 Sep 15;107(6):1365-72.